What is Royalty Pharma's phase 3, tev-408 — research and development commitment?

Royalty Pharma (RPRX) reported phase 3, tev-408 — research and development commitment of $425.00M in Q1 2026.

Products & Services · Research and development commitment

Phase 3, TEV-408 — Research and development commitment

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

How to read this metric

An increase suggests accelerated development efforts or higher costs to reach regulatory milestones, while a decrease may indicate project completion, cost-saving measures, or a shift in strategic priority.

Detailed definition

This metric represents the capital allocation or financial commitment dedicated to the research and development of the T...

Peer comparison

Comparable to R&D expenditure or milestone funding commitments for specific late-stage pipeline assets at other biopharmaceutical or royalty-focused firms.

Metric ID: rprx_segment_phase_3_tev_408_research_and_development_commitment

Historical Data

1 periods

	Q1 '26
Value	$425.00M

Similar Metrics at Other Companies

Roivant SciencesROIV View metric

Eli LillyLLY View metric

United TherapeuticsUTHR View metric

Eli LillyLLY View metric

Roivant SciencesROIV View metric

AmgenAMGN View metric

Frequently Asked Questions

What is Royalty Pharma's phase 3, tev-408 — research and development commitment?: Royalty Pharma (RPRX) reported phase 3, tev-408 — research and development commitment of $425.00M in Q1 2026.
What does phase 3, tev-408 — research and development commitment mean?: The amount of capital invested in the late-stage clinical development of the TEV-408 pharmaceutical candidate.